Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of ...

(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

This visceral drama felt like the definitive show of the first Trump presidency. But, argues Fiona Sturges, the further it’s ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Reports Q1 reveue $6.7B, consensus $6.81B. “Gilead (GILD) had a strong start to the year driven by excellent commercial and clinical execution ...

(GILD) on Thursday reported first-quarter earnings of $1.32 billion. The Foster City, California-based company said it had net income of $1.04 per share. Earnings, adjusted for costs related to ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

The Gilead Road Bridge over I-77 in Huntersville, NC, will be closed from May 2 at 9 p.m. to May 5 at 6 a.m. for interchange ...

Looking ahead, Gilead Sciences cut its full-year earnings outlook to $5.65 to $6.05 a share from a prior range of $5.95 to $6.35 a share. Analysts had been expecting full-year earnings of $6.22. The ...